PNS Training Grants

2024 Submission Period is Closed. Next Submission Period Begins Fall 2024.

2024 PNS Training Grant Submission Closed. Next Submission Period Begins Fall 2024.

In alignment with our mission, one of the goals of the Peripheral Nerve Society is to help researchers’ careers and foster excellence in peripheral nerve research including clinical, translational, and basic science.

This grant will support:

  • A junior clinical investigator to acquire or consolidate expertise in clinical observational studies, clinical outcome measures and/or in clinical diagnostic and therapeutic development.
  • A junior scientist or junior clinician scientist to develop expertise and knowledge in peripheral nerve research by answering key questions in Schwann cell/axonal biology and/or by elucidating relevant disease pathomechanisms.

Who is Eligible to Apply

  • All applicants must have a documented interest in and commitment to peripheral neuropathy research.
  • Candidates who hold an MD or PhD or MD, PhD, or equivalent degree (e.g., neurology trainee with a documented interest in peripheral neuropathies) or candidates with less than 3 years of a faculty position are eligible to apply.
  • Applicants who are in the process of defending their doctoral thesis but who have not yet formally been awarded the doctoral degree will also be considered eligible to apply.
  • The applicant must conduct the training in a center/institution where he/she has NOT been trained in previously. This includes institutions that are under the umbrella of another institution (ie. Mass General and Mass General Bringham).
  • Those awarded a grant will be required to become a PNS member.



Prospective applicants are required to select a mentor and to develop with the mentor the project to be submitted before applying for the grant.

List of Approved Mentors

Prospective mentors must refer to the mentorship criteria below and contact education@pnsociety.com in order to be added to this approved list.

Paula Alberti, MD, PhD

Institution Name: University of Milano-Bicocca
Address: Via Cadore 48, Monza, Italy, 20900
Email: paola.alberti@unimib.it 
Phone: +393333544297
Institution/lab Website: https://en.unimib.it/paola-alberti 
ORCID#: 0000-0001-6106-6183

Activities, Research Interests, and Primary Focus:

My primary focus is on toxic neuropathies, specifically CIPN.

I am in charge of both clinical and preclinical CIPN research projects. At a preclinical level I have developed a line of research that applies morpho-functional techniques to study axonal damage mechanisms, with particular attention to ion channel dysfunctions. To this end I learnt nerve excitability testing from Prof Hugh Bostock, PhD in London (UCL). At a clinical level I am Principal Investigator of national and international studies aimed at investigating various clinical and epidemiological aspects of CIPN: ICAVS (NCT04633655), CIPN COST (NCT04986891) and NEUPER study (NCT05088681). I was a visiting research fellow at Johns Hopkins University (2015) and the University of Maryland (2018). I am currently a member of the board of the Italian Association of Peripheral Neuropathies (ASNP), vice chair of the junior committee of the Peripheral Nerve Society (PNS) and represented of this committee within the Toxic Neuropathy Consortium of PNS, chair of the neurological complication study group of the Multinational Association for Supportive Care in Cancer (MASCC). I am author of 82 publications in international peer-review journals (H-index: 33 on Scopus).

I was recently granted 250,000 euros to conduct, as PI, a preclinical research project (in vitro and in vivo techniques are applied), aiming at dissecting mechanisms of axonal damage, titled “Sodium-calcium exchanger (NCX) and ion channels: pivotal elements leading to axonal damage in peripheral nerves?

David Bennett, MD, PhD

Institution Name: University of Oxford
Address: John Radcliffe Hospital, Oxford, South East, OX39DU, UK
Email: david.bennett@ndcn.ox.ac.uk
Phone: +447941461237
Institution/lab Website: https://www.ndcn.ox.ac.uk/team/david-bennett
ORCID#: 0000-0002-7996-2696

Activities, Research Interests, and Primary Focus:
David Bennett is head of the Division of Clinical Neurology at the University of Oxford and a senior research fellow of Green Templeton College. His research focus is to understand the pathogenesis of neural injury and neuropathic pain and ultimately improve the clinical management of this debilitating condition. He takes a translational approach ranging from cell based models to human psychophysics and clinical cohorts. He administers a specialist neuropathic pain clinic based at Oxford University hospitals. He has led the identification of novel clinical neuropathies and inherited pain channelopathies. He leads major international and national consortia including DOLORisk and PAINSTORM investigating risk factors and determinants of neuropathic pain.

Alessandra Bolino, PhD

Institution Name: Vita-Salute San Raffaele University
Address: Via Olgettina 58, Milan, 20132, Italy
Email: bolino.alessandra@hsr.it
Phone: 390226434743

Institution/lab Website: https://www.unisr.it/en/docenti/b/bolino-alessandra
ORCID#: 0000-0002-8980-4878

Activities, Research Interests, and Primary Focus:
Research in my laboratory seeks to clarify the molecular mechanisms that regulate membrane trafficking and homeostasis during myelin biogenesis using in vivo and ex vivo models of myelination and to exploit these mechanisms to design therapeutical strategies for CMT neuropathies. Research in my lab is now focused in assessing the efficacy of viral mediated gene therapy to treat severe forms of autosomal recessive CMT diseases.

Craig Blackston, MD, PhD

Institution Name: Massachusetts General Hospital / Harvard Medical School
Address: 114 16th Street, Room 2005, Charlestown, Massachusetts, 02129, USA
Email: cblackstone@mgh.harvard.edu
Phone: 3012198305
Institution/lab Website: https://researchers.mgh.harvard.edu/profile/24762014/Craig-Blackstone
ORCID#: 0000-0003-1261-9655

Activities, Research Interests, and Primary Focus:
I am Vice Chair for Research in the Dept of Neurology. My primary focus is neurogenetic disorders, particularly long axonopathies such as hereditary spastic paraplegias. Mostly cellular studies, but some rodent models.

Guido Cavaletti, MD

Institution Name: Università di Milano-Bicocca
Address: via Cadore48, Monza, MD, 20900, Italy
Email: guido.cavaletti@unimib.it
Phone: +390264488039
Institution/lab Website: https://www.enu.dcmt.unimib.it/
ORCID#: 0000-0003-4128-2406

Activities, Research Interests, and Primary Focus:
My primary interest is in the investigation of the peripheral and central side effects of anticancer chemotherapy, with a translational approach that starts from the clinical need and moves to the in vitro and in vivo experimental paradigms. I was a panelist or I was invited to give lectures at the US National Cancer Institute, National Institute of Health, FDA, American Society of Clinical Oncology, European Society for Medical Oncology, and American Academy of Neurology. I am the Chair of the Toxic Neuropathy Consortium of the Peripheral Nerve Society and authored more than 350 full papers in peer-reviewed international journals with more than 16000 citations (current Scopus h-index = 71). I am involved since 2001 as tutor/supervisor in the activities of the PhD in Neuroscience at my University, and I was the program director in the period 2007-2019

Michael Coleman, PhD

Institution Name: University of Cambridge, UK
Address: John van Geest Centre for Brain Repair, Cambridge, CB2 0PY, UK
Email: mc469@cam.ac.uk
Phone: +44-7595-446466
Institution/lab Website: https://colemanlab.brc.cam.ac.uk
ORCID#: 0000-0002-9354-532X

Activities, Research Interests, and Primary Focus:
Axon degeneration mechanisms regulated by SARM1, NMNATs and NAD metabolism. Polyneuropathies. ALS. Peripheral neuropathies. hiPSC-derived neurons. Mouse primary neuron cultures.

Andrea Cortese, MD, PhD

Institution Name: University College London
Address: Queen Square, London, WC1N 3BG, UK
Email: andrea.cortese@ucl.ac.uk
Phone: 0044 7464 130564
Institution/lab Website: https://www.neurogenetics.co.uk/
ORCID#: 0000-0002-2208-5311

Activities, Research Interests, and Primary Focus:
My research focuses on the discovery and modelling of novel causes of inherited neuropathies and neurological diseases. Key output of the lab were the identification and ongoing clinical and molecular characterisation of RFC1 repeat expansion disease and SORD neuropathy and, more recently ABCD3 repeat causing OPDM. Current research topic and areas: novel sequencing technologies to investigate the missing heritability of neuromuscular diseases, pathomechanism of RFC1 disease, genetic modifiers of TTR amyloidosis, SORD mouse model.

Stefanie Geisler, MD

Institution Name: Washington University Saint Louis Medical School
Address: 660 S. Euclid Ave, Box 8111, St. Louis, Missouri, 63110, USA
Email: geislers@wustl.edu
Phone: 1-314-362-4955
Institution/lab Website: https://sites.wustl.edu/geislerlab/
ORCID#: 0000-0002-5603-0810

Activities, Research Interests, and Primary Focus:
I am a physician-scientist and Director of the Center of Excellence for Neuropathy Treatment and Research (C.E.N.T.R.) at Washington University School of Medicine in St. Louis, MO. I am passionate about the lives of patients with peripheral neuropathy through basic, translational and clinical research. My lab focuses on molecular mechanisms underlying different aspects of peripheral neuropathy with the goal to identify new therapeutic avenues that can be translated into effective treatment strategies. We take bench-to-bedside and bedside-to-bench approaches to investigate chemotherapy-induced and small fiber neuropathies as models, in order to gain fundamental insights and develop broad-ranging therapies that benefit patients with many different forms of peripheral neuropathy. I am PI on an NIH funded R37 evaluating novel therapies for chemotherapy-induced neuropathy in a mouse model. I am also site PI of the Peripheral Neuropathy Research Registry, and was site PI of several national and international clinical trials for peripheral neuropathy. I have published more than 20 peer reviewed papers and have been continuously funded by the NIH since 2015 and by intra-mural and extramural funding agencies.

Katrin Hahn, MD

Institution Name: Universitätsmedizin Charité
Address: Charitéplatz 1, Berlin, 10117, Germany
Email: katrin.hahn@charite.de
Phone: +49 30 450660834
Institution/lab Website:
ORCID#: 0000-0002-6013-0072

Activities, Research Interests, and Primary Focus:
hereditary neuropathy, amyloidosis, myositis.

Rita Horvath, MD, PhD

Institution Name: University of Cambridge
Address: Robinson Way, Cambridge, Cambridgeshire, CB2 0PY, UK
Email: rh732@medschl.cam.ac.uk
Phone: +447934450687
Institution/lab Website: https://www-neurosciences.medschl.cam.ac.uk/horvathlab/dr-rita-horvath/
ORCID#: 0000-0002-9841-170X

Activities, Research Interests, and Primary Focus:
I am a clinical academic neurologist. I have been working for >15 years in the field of CMT. I set up a large CMT clinic in Newcastle upon Tyne and performed molecular biomarker studies and other functional experiments in the filed of inherited peripheral neuropathies such as distal hereditary motor neuropathies and mitochondrial forms of CMT.

Ruth Huizinga, PhD

Institution Name: Erasmus MC, University Medical Center
Address: Dr Molewaterplein 50, Rotterdam, 3015 GD, The Netherlands
Email: h.huizinga@erasmusmc.nl
Phone: +31107043190
Institution/lab Website: https://www.immunology.nl/research/bart-jacobs-ruth-huizinga/

Activities, Research Interests, and Primary Focus:
Immune-mediated neuropathies – immunology.

Zhahirul Islam, PhD

Institution Name: ICDDR, B
Address: 68, Shaheed Tajuddin Saranii, Dhaka, 1212, Bangladesh
Email: zislam@icddrb.org
Phone: 01710957036
Institution/lab Website: https://www.icddrb.org/
ORCID#: 0000-0003-0935-8079

Activities, Research Interests, and Primary Focus:
Pathogenesis of GBS.

Jonathan Leckenby, MD, PhD

Institution Name: University of Rochester Medical Center
Address: 601 Elmwood Ave, Rochester, NY, 14642, USA
Email: jonathan_leckenby@urmc.rochester.edu
Phone: 5853010925
Institution/lab Website: https://www.urmc.rochester.edu/labs/leckenby-lab.aspx

Activities, Research Interests, and Primary Focus:
Peripheral nerve regeneration, chemotherapy induced peripheral neuropathy.

Ying Liu, MD, PhD

Institution Name: Johns Hopkins University
Address: 855 N. Wolfe Streeet, Rangos Bldg, room 292, Baltimore, Maryland, 21205, USA
Email: yliu41@jh.edu
Phone: +1 4103360539
Institution/lab Website: https://www.jhu.edu/
ORCID#: 0000-0003-1889-9715

Activities, Research Interests, and Primary Focus:
My main clinical focus at the Johns Hopkins Department of neurology, Cutaneous Nerve Laboratory is evaluation the skin biopsy with autonomic neuropathy. As a team leader, I work with the colleagues to establish few new biomarkers to help with clinical diagnosis for subtypes of patient population, such as patients with movement disorder or orthostatic hypotension, patients with autonomic dysfunction and patients with dementia. My current research efforts include diabetic autonomic neuropathy, cardiac autonomic neuropathy and chemotherapy-induced autonomic neuropathy. Specific projects include combined analysis of autonomic neuropathy and sweat function test in diabetic transgenic animal models and chemotherapty-induced neuropathy animal models and evaluation the risk factors influencing autonomic fiber degeneration in human and experimental animal models. I have successfully completed a biomarker project in autonomic neuropathy as a principal investigator (PI), and currently a PI on another project examining the biomarker for movement disorder. In addition, I am the co- PI and co-investigator for a multi-site clinical trial studies. My continuing work seeks to deepen the understanding the mechanisms of neuropathy using genetic model systems. The studies involve developing the biomarker for cardiac autonomic neuropathy and age-related neurodegenerative diseases and studying the potential therapeutic strategy for diabetic neuropathy as well as chemotherapy-induced neuropathy.

Daniela Maria Menichella, MD, PhD

Institution Name: Northwestern University
Address: 107 Central Park Ave, Wilmette, IL, 60091, USA
Email: d-menichella@northwestern.edu
Phone: 18478903741
Institution/lab Website:
ORCID#: 0000-0002-2955-175X

Activities, Research Interests, and Primary Focus:
Dr. Menichella. Daniela Maria received her MD and PhD from the University of Milan, Italy. She was a postdoctoral fellow at Wayne State University and Harvard Medical School. Dr. Menichella graduated from the Neurology Residency Program at Northwestern University in Chicago and is an Associate Professor of Neurology and Pharmacology at Northwestern University. She is the director of the Peripheral Neuropathy Multidisciplinary Clinic and the Charcot-Marie-Tooth Association Center for Excellence. She actively engages in basic science and translational research, including NIH NeuroNext Clinical trials. Dr. Menichella is the Principal Investigator of an NIH-funded laboratory investigating the molecular and cellular mechanisms underlying neuropathic pain and axonal degeneration in hereditary and acquired peripheral neuropathies, focusing on Painful Diabetic Neuropathy. Towards designing more effective therapeutics, Dr Menichella’s laboratory takes advantage of an integrated approach combining pain behavioral tests, electrophysiology studies, in vitro and in vivo calcium imaging studies, confocal studies, chemogenetics and single-cell RNA sequencing with conditional and transgenic mouse models. Her laboratory has recently validated therapeutic targets using human tissue, including DRG and skin biopsy.

Theodore Price, PhD

Institution Name: University of Texas at Dallas
Address: 800 W Campbell Rd, Richardson, TX, 75080
Email: theodore.price@utdallas.edu 
Phone: +19728834311
Institution/lab Website: https://paincenter.utdallas.edu/ 

Activities, Research Interests, and Primary Focus:
My lab is focused on studying the rodent and human peripheral nervous system with an emphasis on pain. We are funded by many NIH grants to identify and validate pain mechanisms and targets. We also do drug discovery for pain with the goal of developing new, non-opioid drugs for pain.

Luis Querol, MD, PhD

Institution Name: Hospital de la Santa Creu i Sant Pau
Address: Sant Quinti 77, Barcelona, Catalonia, 08041, Spain
Email: lquerol@santpau.cat
Phone: +34647489267
Institution/lab Website: www.neuromuscularbcn.org
ORCID#: 0000-0002-4289-8264

Activities, Research Interests, and Primary Focus:
Autoantibodies, Biomarkers, Inflammatory neuropathies.

Michael Shy, MD

Institution Name: University of Iowa
Address: 200 Hawkins Drive, Iowa City, Iowa, 52242, USA
Email: michael-shy@uiowa.edu
Phone: 248-730-0136
Institution/lab Website:
ORCID#: 0000-0001-8460-6971

Activities, Research Interests, and Primary Focus:
Genetic neuropathies, translational research, Schwann cell biology, clinical outcome measures, natural history studies.

Nathan Staff, MD, PhD

Institution Name: Mayo Clinic
Address: 200 First Street SW, Rochester, Minnesota, 55905, USA
Email: staff.nathan@mayo.edu
Phone: +1 507-284-2511
Institution/lab Website: https://www.mayo.edu/research/labs/translational-neuromuscular-disease-research/overview

Activities, Research Interests, and Primary Focus:
I am a neuromuscular clinician-scientist with primary focus on chemotherapy-induced peripheral neuropathy and ALS; however, I also have projects in CMT. My laboratory uses human iPSC-derived neuronal models to understand pathomechanisms of disease. Fellow would be exposed to the overall translational research group at Mayo Clinic that spans basic science to clinical trials.

Charlotte Sumner, MD

Institution Name: Johns Hopkins University School of Medicine
Address: 959 Fell Street, Baltimore, MD, 21205, USA
Email: csumner1@jhmi.edu
Phone: 4109086919
Institution/lab Website: https://www.sumnerlab.com/
ORCID#: 0000-0001-5088-6012

Activities, Research Interests, and Primary Focus:
Laboratory based research in CMT2C and spinal muscular atrophy. Natural history study of patients with TRPV4 mutations.

Stefano Tamburin, MD, PhD

Institution Name: University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences
Address: GB Rossi Hospital, P.le Scuro 10, Verona, VR, 37134, Italy
Email: stefano.tamburin@univr.it
Phone: +393475235580
Institution/lab Website: https://www.dnbm.univr.it/?ent=persona&id=6253&lang=en
ORCID#: 0000-0002-1561-2187

Activities, Research Interests, and Primary Focus:
The main areas of research and clinical interest include the peripheral nervous system diseases, neuropathic pain, central and peripheral neurotoxicity to chemotherapy for cancer. The experimental approach is integrative and includes the evaluation of clinical features, neurophysiological and nerve imaging investigations, psychophysical aspects, neurorehabilitation, advanced diagnostic and therapeutic technologies and use of engineering and computer tools (information and communication technology, internet of the medical things, artificial intelligence) to improve diagnosis and therapy.

Camiel Verhamme, MD, PhD

Institution Name: Amsterdam UMC, location AMC
Address: Meibergdreef 9, Amsterdam, 1100DD, The Netherlands
Email: c.verhamme@amsterdamumc.nl
Phone: 00-31-20-5669111
Institution/lab Website: https://researchinformation.amsterdamumc.org/en/organisations/neurology
ORCID#: 0000-0002-0444-574X

Activities, Research Interests, and Primary Focus:
I am neurologist / clinical neurophysiologist at the Amsterdam UMC, location AMC, and combining a clinical position with emphasis on clinical neurophysiology with a neuromuscular outpatient clinic. My research focuses on improving the diagnosis of peripheral nerve and muscle disorders. Here the emphasis is on the use of neurophysiological techniques (EMG), including ultrasound. and incorporating machine. My research focuses on inflammatory disorders, such as immune-mediated neuropathies (CIDP, MMN) and idiopathic inflammatory myopathies (myositis), and I contribute to research in the field of hereditary polyneuropathies (CMT/HMSN). I also conduct research on improving the treatment of peripheral nerve disorders. As one of the principal investigators, I lead the DISTRICTS study: a nationwide study, investigating the best treatment for carpal tunnel syndrome. https://researchinformation.amsterdamumc.org/en/persons/camiel-verhamme

Douglas Zochodne, MD, FRCPC

Institution Name: University of Alberta
Address: 7-132 Clinical Sciences Bldg; 11350-83 Ave, Edmonton, Alberta, T6G 2G3, Canada
Email: zochodne@ualberta.ca
Phone: 780-248-1928
Institution/lab Website: https://apps.ualberta.ca/directory/person/zochodne
ORCID#: 0000-0003-1692-5983

Activities, Research Interests, and Primary Focus:
peripheral neurobiology; axon regeneration diabetic polyneuropathy; neuropathies

Stephan Zuchner, PhD

Institution Name: University of Alberta
Address: 1501 NW 10th Ave,Miami,FL, 33136, USA
Email: szuchner@med.miami.edu 
Phone: 3052432281
Institution/lab Website: https://med.miami.edu/faculty/stephan-zchner-md-phd
ORCID#: 0000-0002-8498-5235

Activities, Research Interests, and Primary Focus:
inherited peripheral nerve genetics, biology, and therapy.

Mentorship Criteria

  • The mentor must be a peripheral nerve scientist or clinician
  • The mentor must be an active PNS member, having maintained a membership for a minimum of 6 months and current with dues payments.
  • The mentor must have a consolidated publication track record.
  • The mentor must have prior history with mentorship and students.
  • The mentor’s institution must have co-funding for the project available.
  • The mentor must be open to hosting a training grant candidate that has not been trained at the institution before.
  • The mentor’s project may not be funded exclusively by a company with commercial interests. The mentor must not have more than $10,000 USD in stock in a company that has provided funding for the project. The PI and host institution will retain the intellectual property rights.

If the proposed project benefits from scientific exchange and training across two different centers, mobility between two mentors is allowed. This must be justified by the two mentors at the time of the application and the travel between the two labs should be covered by the mentors.

Application Instructions

The grant application is accessible via the PNS Submission Portal. Applicants will be asked to prepare the following:

Application Instructions

The grant application is accessible via the PNS Submission Portal. To access it, click the ‘2024 Training Grant Application’ button below. Applicants will be asked to prepare the following:

1. Letter of Intent (2-pages maximum)

Please specify your interest and commitment to PNS research; your previous experience and achievements; why you are applying to this program, and what do you expect from this program to further consolidate your career as a scientist or clinician.

2. CV

**Follow the NIH Biosketch format. Please use the Non-Fellowship Version

Please detail your previous and current experience and mentors (with institutions/centers).

3. Project Application

Basic Science Applicants: Please provide an outline of the proposal (6 pages maximum) structured as follows:

  • Specific aims and rationale of the proposed project
  • Background and preliminary results
  • Experimental plan
  • Expected results – pitfalls and alternative plans
  • Timeline and milestones (Gantt chart required)
  • References must be included in a separate section with no length limits

Clinical Applicants (for clinical observational studies, clinical outcome measures, natural history studies or novel diagnostic or therapeutic technologies): Please provide an outline of the proposal structured as follows:

  • Background and objectives
  • Study Design, Population of Study (Inclusion and Exclusion criteria) and Methods
  • Expected outcomes/results
  • Relevance for the field and plans for future development of the project
4. Mentor Documents

Additionally, the applicants must obtain from the mentor(s) the following documents:

  1. CV: **Please follow the NIH Biosketch format. Please use the Non-Fellowship Version. Please specify your experience in supervising clinicians/scientists doing research/clinical research training.
  2. Mentor(s) Letter of Support: Mentor(s) should include detailed training program and expected outcomes.
  3. Host Institution(s) Letter of Support: The host institution(s) must acknowledge they will:
    • Receive the mentee’s salary and living expense funds directly from the PNS (for further disbursement to the mentee).
    • Provide co-funding for the project.
    • Accept the terms of the PNS Grant Agreement.
    • Provide direct support to the mentee if they need to meet specific requirements to work at the host institution.
    • Note in the letter if the incorporation could be delayed, a reasonable alternative timeline for the development of the project and justify that the delay will not significantly alter the development of the project. The PNS expects in all usual circumstances projects to commence by 31 January of the year following the award of the grant.
    • Provide an accurate gross salary range (converted to USD) for a mentee working at the host institution for a year. The PNS funds will cover salary and contribute towards living and travel expenses.

Questions? Please contact education@PNSociety.com.

Additional Information



Funding for these awards is designed to cover salary and a contribution to travel and living expense costs for the trainees up to $75,000 USD/year (see budget, application section). It is not intended to support the laboratory or mentor. Other funding will need to be available to demonstrate that the project can be accomplished. Funds will be distributed directly to the PI of the host institution (mentor) for further disbursement to the mentee.



The duration is one year (for a clinical-only project) or two years (for a clinical research or basic science project). The project must commence by 31 January of the year following the award of the grant.


Evaluation Procedure

An ad-hoc selection committee including scientists and clinicians of the PNS Society will oversee the selection process. The evaluation will include two stages.

Stage 1: In the first stage, applications will be evaluated by reviewers who are scientists and clinicians, members of the PNS, and, if necessary, by ad hoc appointed reviewers selected from among internationally recognized experts.  Applications will be scored considering adherence to the PNS mission, originality, feasibility, and scientific excellence of the proposed project, along with candidate CV and mentor’s CV and host institution.

Stage 2: In the second stage, top scored applicants will be interviewed by the committee to defend their proposal and clarify the committee’s questions and concerns.

The PNS will award one training grant in clinical and one in basic science per funding year. Recipients of the PNS training grant program must be active PNS Members (dues paid).

To view the full grant scoring guidelines, please click here.



Both the grantee and the mentor(s) must submit separate reports at 6 and 12 months for the 1-year grant and once a year for the 2-years grant. Successful programs in basic science are expected to generate sufficient preliminary data to apply for other funding sources such as the NIH K08 programs, EU-individual fellowships or equivalent.

All grantees are expected to submit abstracts to the PNS annual meeting to report the progress of their training activities.

Grants Committee

Alessandra Bolino, PhD
Vita-Salute San Raffaele University,
Milan, Italy

Vice Chair
Luis Querol, MD, PhD
Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain

  • Paola Alberti, MD PhD, University of Milano-Bicocca, Milan, Italy
  • Margarita Calvo, MD PhD, Pontificia Universidad Católica de Chile, Santiago, Chile
  • Catharina Faber, MD PhD, Maastricht University Medical Centre, Maastricht, Netherlands
  • Chris Gibbons, MD, Beth Israel Deaconess Medical Center, Boston, MA, USA
  • Ruth Huizinga, PhD, Erasmus MC University Medical Center, Rotterdam, Netherlands
  • Satoshi Kuwabara, MD PhD, Graduate School of Medicine, Chiba University, Chiba, Japan
  • Steven Scherer, MD PhD, University of Pennsylvania, Philadelphia, PA, USA
  • John SvarenPhD, University of Wisconsin-Madison, Madison, WI, USA
  • Vincent Timmerman, PhD, University of Antwerp, Antwerp, Belgium